Effect of Differently Fed Farmed Gilthead Sea Bream Consumption
Effect of Fish Consumption Enriched With Biologically Active Lipids From Olive Pomace, on Cardiovascular Risk Factors in Apparently Healthy Volunteers
1 other identifier
interventional
38
1 country
1
Brief Summary
The trial was a double-blind randomized dietary intervention study with a 1:1 allocation ratio, conducted in accordance with the Declaration of Helsinki. This study compared two treatments, i.e., farmed fish fed with olive pomace enriched diet (enriched fish; EF) versus farmed fish fed with fish oil diet (conventional fish; CF), using a crossover design. The study lasted 22 weeks; treatment period one (8 weeks, mid-January-end of March), washout period (6 weeks), and treatment period two (8 weeks, mid-May-end of July). The participants were equally distributed to the two treatments along treatment periods. Eligible subjects were all adults aged between 30 and 65 years old with a body mass index (BMI) between 24.0 and 31.0 kg/m2 who met the eligibility criteria for habitual fish consumption (\<150 g of cooked fish per week). Exclusion criteria were pregnancy, current or recent weight loss effort, use of dietary supplements and being under treatment for any medical disorder. Subjects were allowed to use medical treatment for thyroid gland disorders, iron or folic acid supplements, contraceptives or hormone replacement therapy (HRT) for women, provided they would continue receiving their medication throughout the study. The aim of the study was to evaluate the effects of consumption of fillets from differently fed farmed gilthead sea bream on markers of cardiometabolic health such as platelet aggregation, circulating haemostatic markers, markers of inflammation and oxidative stress.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Dec 2012
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2014
CompletedFirst Submitted
Initial submission to the registry
June 9, 2022
CompletedFirst Posted
Study publicly available on registry
June 14, 2022
CompletedJune 14, 2022
June 1, 2022
12 months
June 9, 2022
June 9, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Change from baseline of adenosine diphosphate-induced platelet aggregation at 8 weeks
Efficiency concentration fifty of adenosine diphosphate-induced platelet aggregation (microM) will be assessed by light transmittance aggregometry
0 (baseline) and 8 weeks
Change from baseline of platelet activating factor-induced platelet aggregation at 8 weeks
Efficiency concentration fifty of platelet activating factor-induced platelet aggregation (microM) will be assessed by light transmittance aggregometry
0 (baseline) and 8 weeks
Change from baseline of thrombin-induced platelet aggregation at 8 weeks
Efficiency concentration fifty of thrombin-induced platelet aggregation (microM) will be assessed by light transmittance aggregometry
0 (baseline) and 8 weeks
Change from baseline in of plasminogen activator inhibitor-1 activity at 8 weeks
Plasminogen activator inhibitor-1 activity (mAU/mL) will be measured in blood samples using commercially available ELISA kits
0 (baseline) and 8 weeks
Change from baseline in soluble P-selectin levels at 8 weeks
Soluble P-selectin levels (ng/mL) will be measured in blood samples using commercially available ELISA kits
0 (baseline) and 8 weeks
Study Arms (2)
Conventional fish
ACTIVE COMPARATORThis arm will consume 2 portions of gilthead seabream fed with conventional diet. Each portion weighed on average 380 g (raw, quantity of edible fillet approximately 170 g). Participants were instructed to consume fish twice weekly, one portion at a time.
Enriched fish
EXPERIMENTALThis arm will consume 2 portions of gilthead seabream fed with olive pomace enriched diet. Each portion weighed on average 380 g (raw, quantity of edible fillet approximately 170 g). Participants were instructed to consume fish twice weekly, one portion at a time.
Interventions
Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using a diet enriched with olive pomace. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
Eligibility Criteria
You may qualify if:
- Age 30-65 years old
- Body Mass Index between 24-31 kg/m\^2
- Habitual fish consumption: \<150 g of cooked fish per week
You may not qualify if:
- Pregnancy
- Current or recent weight loss effort
- Use of dietary supplements
- Being under treatment for any medical disorder
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Harokopio Universitylead
- Nireus Aquaculturecollaborator
- National and Kapodistrian University of Athenscollaborator
Study Sites (1)
Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University
Kallithea, Attica, 17671, Greece
Related Publications (1)
Ntzouvani A, Antonopoulou S, Fragopoulou E, Kontogianni MD, Nomikos T, Mikellidi A, Xanthopoulou Mu, Kalogeropoulos N, Panagiotakos D. Effect of Differently Fed Farmed Gilthead Sea Bream Consumption on Platelet Aggregation and Circulating Haemostatic Markers among Apparently Healthy Adults: A Double-Blind Randomized Crossover Trial. Nutrients. 2021 Jan 20;13(2):286. doi: 10.3390/nu13020286.
PMID: 33498445BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Smaragdi Antonopoulou, PhD
Department of Nutrition and Dietetics, Harokopio University
- STUDY CHAIR
Elizabeth Fragopoulou, PhD
Department of Nutrition and Dietetics, Harokopio University
- STUDY CHAIR
Tzortzis Nomikos, PhD
Department of Nutrition and Dietetics, Harokopio University
- STUDY CHAIR
Meropi D Kontogianni, PhD
Department of Nutrition and Dietetics, Harokopio University
- STUDY CHAIR
Michael Georgoulis, PhD
Department of Nutrition and Dietetics, Harokopio University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor in Biochemistry
Study Record Dates
First Submitted
June 9, 2022
First Posted
June 14, 2022
Study Start
December 1, 2012
Primary Completion
November 30, 2013
Study Completion
February 28, 2014
Last Updated
June 14, 2022
Record last verified: 2022-06
Data Sharing
- IPD Sharing
- Will share
Deidentified individual participant data will be shared to investigators for the purpose of individual participant data meta-analysis, provided that the proposed use of the data has been approved by the Study Principal Investigator. Proposals should be directed to antonop@hua.gr. To gain access, data requestors will need to sign a data access agreement.